Vizgen, a Cambridge, Mass.-based biotech company developing solutions for next-generation spatially resolved, single-cell transcriptomics, closed a $14m Series A financing.
The round was led by ARCH Venture Partners and Northpond Ventures. The company intends to use the funds to accelerate productization of its patented MERFISH (multiplexed error-robust fluorescence in situ hybridization) platform with the goal of empowering and commercializing this technology for research and development and eventual clinical use.
Vizgen is a biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. Developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator and David B. Arnold Professor of Science at Harvard University, MERFISH is a quantitative and genome-scale multiplexed imaging technology for identifying nucleic acids in their native cellular and tissue environment.
In addition to Dr. Zhuang, the co-founders of Vizgen also include David Walt, Ph.D., Core Faculty at the Wyss Institute at Harvard University, Professor of Pathology at Brigham and Women’s Hospital, and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School and Dr. Jeffrey Moffitt, Ph.D., Investigator at the Program in Cellular and Molecular Medicine at Boston Children’s Hospital and an Assistant Professor in the Department of Microbiology at Harvard Medical School.